Relevant bibliographies by topics / Pylori therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Pylori therapy'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pylori therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pylori therapy"

1

I.M., Saracino, Pavoni M., Zullo A., et al. "Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients." Antibiotics 9, no. 3 (2020): 121. http://dx.doi.org/10.3390/antibiotics9030121.

Full text
Abstract:
Helicobacter pylori (H. pylori) eradication fails in a definite amount of patients despite one or more therapeutic attempts. Curing these patients is progressively more difficult, due to development of antibiotic resistance. Current guidelines suggest testing antibiotic susceptibility in H. pylori isolates following two therapeutic attempts. Aim: to evaluate the development of antibiotic resistance, MIC values trends and therapeutic outcomes in patients who failed at least one H. pylori eradication therapy. Methods: consecutive patients, referred to perform upper gastrointestinal endoscopy (UG
APA, Harvard, Vancouver, ISO, and other styles
2

Fiorini, Giulia, Ilaria Maria Saracino, Angelo Zullo, et al. "Antibiotic Resistance and Therapy for H. pylori Infection in Immigrant Patients Treated in Italy." Journal of Clinical Medicine 9, no. 5 (2020): 1299. http://dx.doi.org/10.3390/jcm9051299.

Full text
Abstract:
Background: Helicobacter pylori (H. pylori) infection is the leading cause of both peptic ulcers and gastric tumors, including low-grade MALT-lymphoma and adenocarcinoma. Although it is decreasing in developed countries, H. pylori prevalence remains high in developing areas, mainly due to low socio-economic levels, and the potential consumption of contaminated water. Moreover, a different pattern of primary antibiotic resistance is expected in their H. pylori isolates, potentially affecting the efficacy of standard eradication therapies. Indeed, a previous study showed the eradication rate fol
APA, Harvard, Vancouver, ISO, and other styles
3

Zullo, Angelo, Vincenzo De Francesco, Annamaria Bellesia, et al. "Bismuth-based Quadruple Therapy Following H. pylori Eradication Failures: a Multicenter Study in Clinical Practice." Journal of Gastrointestinal and Liver Diseases 26, no. 3 (2017): 225–29. http://dx.doi.org/10.15403/jgld.2014.1121.263.zul.

Full text
Abstract:
Background & Aims: Helicobacter pylori (H. pylori) eradication in patients who failed one or more therapeutic attempts remains challenging. This study aimed to assess the efficacy of three-in-one capsules bismuth-based quadruple therapy (Pylera®) in these patients managed in clinical practice.
 Methods: This was a prospective, open-label, multicenter study enrolling consecutive, adult patients with persistent H. pylori infection following at least one standard therapy. All patients received a rescue quadruple therapy with Pylera (3 capsules four times daily) and esomeprazole 20 mg (1
APA, Harvard, Vancouver, ISO, and other styles
4

Di Ciaula, Agostino, Giuseppe Scaccianoce, Marino Venerito, et al. "Eradication Rates in Italian Subjects Heterogeneously Managed for Helicobacter pylori Infection. Time to Abandon Empiric Treatments in Southern Europe." Journal of Gastrointestinal and Liver Diseases 26, no. 2 (2017): 129–37. http://dx.doi.org/10.15403/jgld.2014.1121.262.itl.

Full text
Abstract:
Background & Aims: H. pylori eradication is strongly affected by various factors, including the ongoing antibiotic resistance. We describe a “real life” scenario in patients managed for H. pylori-related conditions, living in a southern Italian region (Apulia), an area with clarithromycin resistance >15%.Methods: 2,224 subjects were studied in two tertiary referral centers in Apulia. Analyses included: reason for referral, H. pylori infection rates (13C-urea breath test – UBT or upper endoscopy), and eradication rates following distinct regimens previously prescribed or prospectively pr
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Yang. "The overview of Clarithromycin treatment for Helicobacter pylori infection." Theoretical and Natural Science 46, no. 1 (2024): 142–48. http://dx.doi.org/10.54254/2753-8818/46/20240604.

Full text
Abstract:
Helicobacter pylori (H. pylori) is a Gram-negative bacillus that causes infections worldwide. Helicobacter pylori's drug resistance and infectivity are vital factors causing Helicobacter pylori infection. The virulence factors of Helicobacter pylori include acid escape virulence factors and epithelial cell colonizing factors, which can directly or indirectly cause chronic gastritis or gastric ulcer. As the resistance of Helicobacter pylori increases, a combination of multiple antibiotics is now the recommended therapy, and clarithromycin is one of them. The production process of clarithromycin
APA, Harvard, Vancouver, ISO, and other styles
6

Shahbazi, Shaahin, Zahra Vahdat Shariatpanahi, and Nourkhoda Sadeghifard. "Effect of Proton Pump Inhibitor Based Triple Therapy with Apple Cider Vinegar on Helicobacter Pylori Eradication." Galen Medical Journal 3, no. 2 (2014): 90–94. http://dx.doi.org/10.31661/gmj.v3i2.97.

Full text
Abstract:
Background: The purpose of this study was to evaluate the effect of apple cider vinegar plus PPI-based triple therapy on eradication of Helicobacter Pylori (H.pylori) infection.Materials and Methods: 116 patients with H. pylori infection were included in this randomized clinical trial. Patients in control group (n=59) received amoxicillin, clarithromycin, and pantaprazole twice daily. Patients in study group (57 patients) received the same regimen plus 30 mL of apple cider vinegar twice daily. The duration of therapy for study and control were 10 and 14 days respectively. Four weeks after the
APA, Harvard, Vancouver, ISO, and other styles
7

Chiba, N., A. Matisko, P. Sinclair, and ABR Thomson. "Helicobacter pylori: From Bench to Bedside." Canadian Journal of Gastroenterology 11, no. 7 (1997): 589–96. http://dx.doi.org/10.1155/1997/975469.

Full text
Abstract:
With the exponential increase in research in the field ofHelicobacter pyloria paradigm shift has occurred. It is now recognized thatH pyloriis a chronic infection of the stomach causing inflammation. Some patients remain asymptomatic, while others may develop dyspepsia, duodenal or gastric ulcer, gastric cancer or a mucosa-associated lymphoid tissue lymphoma. However, the role ofH pyloriin contributing to nonulcer dyspepsia or nonsteroidal anti-inflammatory drug gastropathy remains controversial. An effective vaccine againstH pyloriis years away. Major interest has focused on the questions "wh
APA, Harvard, Vancouver, ISO, and other styles
8

JJ, Ofman, Etchason J, and Fullerton S. "Helicobacter pylori Therapy." Nurse Practitioner 22, no. 5 (1997): 203. http://dx.doi.org/10.1097/00006205-199705000-00035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hartanto, Darius. "Helicobacter pylori Infection: Diagnosis and Therapy." Asian Journal of Medical Sciences 12, no. 4 (2021): 145–48. http://dx.doi.org/10.3126/ajms.v12i4.34506.

Full text
Abstract:
Helicobacter pylori (H. pylori) is a spiral shape gram-negative bacillus and have flagella for motility in mucus environment. H. pylori is microaerophilic organism, slow growing and requires complex growth media in vitro. H. pylori infecting more than 50% populations in worldwide. Prevalence of H. pylori infection is higher in developing countries compared to developed one, and indicates that socioeconomic and living standard may play a major role in the distribution. This study aims to provide an overview of how to diagnose and manage Helicobacter pylori infection. This study reviewed various
APA, Harvard, Vancouver, ISO, and other styles
10

Darius Hartanto. "Helicobacter pylori Infection: Diagnosis and Therapy." Asian Journal of Medical Sciences 12, no. 4 (2021): 145–48. https://doi.org/10.71152/ajms.v12i4.3582.

Full text
Abstract:
Helicobacter pylori (H. pylori) is a spiral shape gram-negative bacillus and have flagella for motility in mucus environment. H. pylori is microaerophilic organism, slow growing and requires complex growth media in vitro. H. pylori infecting more than 50% populations in worldwide. Prevalence of H. pylori infection is higher in developing countries compared to developed one, and indicates that socioeconomic and living standard may play a major role in the distribution. This study aims to provide an overview of how to diagnose and manage Helicobacter pylori infection. This study reviewed various
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pylori therapy"

1

Unge, Peter. "Pharmacological therapy of Helicobacter pylori infection /." Linköping : Univ, 2002. http://www.bibl.liu.se/liupubl/disp/disp2002/med734s.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Millson, Charles Edward. "Photodynamic therapy for the treatment of helicobacter pylori infection." Thesis, King's College London (University of London), 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.281686.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Silva, Fernando Marcuz. "Reinfecção pelo Helicobacter pylori em pacientes brasileiros com úlcera péptica, em seguimento de 5 anos." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5147/tde-01092009-135137/.

Full text
Abstract:
Introdução: A reinfecção pelo Helicobacter pylori em países em desenvolvimento parece ser maior do que nos países desenvolvidos. O retratamento da bactéria e o controle periódico de cura são necessários, quando elevadas taxas de reinfecção são verificadas. O objetivo do trabalho foi determinar a taxa anual de reinfecção, em pacientes brasileiros com úlcera péptica, num seguimento de cinco anos. Métodos: Pacientes com úlcera péptica, diagnosticada por endoscopia digestiva alta e infecção pelo Helicobacter pylori documentada por histologia, teste da urease, reação em cadeia da polimerase e teste
APA, Harvard, Vancouver, ISO, and other styles
4

Morgner, Andrea, Ekkehard Bayerdörffer, Christian Thiede, et al. "Bedeutung der Helicobacter-pylori-Infektion für die Pathogenese und Therapie von MALT-Lymphomen des Magens." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-134075.

Full text
Abstract:
Seit 1983 ist das Konzept des Mukosa-assoziierten lymphatischen Gewebes (MALT) im Magen auf dem Boden einer chronischen Helicobacter(H.)-pylori-Infektion bekannt. Viele epidemiologische, biologische und molekulargenetische Studien haben die Rolle von H. pylori in der Lymphomgenese unterstützt. Bis heute wurden weltweit mehr als 650 Patienten mit gastralem MALT-Lymphom und H.-pylori-Infektion antibiotisch behandelt. Bei etwa 75% der Fälle kann mit Hilfe dieser Therapie eine komplette Lymphomremission induziert werden. Klinische prädiktive Faktoren helfen dabei, Patienten bezüglich ihres Risikos
APA, Harvard, Vancouver, ISO, and other styles
5

Yu, Di. "Adenovirus for Cancer Therapy : With a Focus on its Surface Modification." Doctoral thesis, Uppsala universitet, Klinisk immunologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-203662.

Full text
Abstract:
Adenovirus serotype 5 (Ad5) is widely used as an oncolytic agent for cancer therapy. However, its infectivity is highly dependent on the expression level of coxsackievirus-adenovirus receptor (CAR) on the surface of tumor cells. We engineered Ad5 virus with the protein transduction domain (PTD) from the HIV-1 Tat protein (Tat-PTD) inserted in the hypervariable region 5 (HVR5) of the hexon protein in the virus capsid. Tat-PTD-modified Ad5 shows a dramatically increased transduction level of CAR-negative cells and bypassed fiber-mediated transduction. It also overcomes the fiber-masking problem,
APA, Harvard, Vancouver, ISO, and other styles
6

Morgner, Andrea, Ekkehard Bayerdörffer, Christian Thiede, et al. "Bedeutung der Helicobacter-pylori-Infektion für die Pathogenese und Therapie von MALT-Lymphomen des Magens." Karger, 2002. https://tud.qucosa.de/id/qucosa%3A27560.

Full text
Abstract:
Seit 1983 ist das Konzept des Mukosa-assoziierten lymphatischen Gewebes (MALT) im Magen auf dem Boden einer chronischen Helicobacter(H.)-pylori-Infektion bekannt. Viele epidemiologische, biologische und molekulargenetische Studien haben die Rolle von H. pylori in der Lymphomgenese unterstützt. Bis heute wurden weltweit mehr als 650 Patienten mit gastralem MALT-Lymphom und H.-pylori-Infektion antibiotisch behandelt. Bei etwa 75% der Fälle kann mit Hilfe dieser Therapie eine komplette Lymphomremission induziert werden. Klinische prädiktive Faktoren helfen dabei, Patienten bezüglich ihres Risikos
APA, Harvard, Vancouver, ISO, and other styles
7

Hiroi, Shinzo. "Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real world data." Kyoto University, 2018. http://hdl.handle.net/2433/232454.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Barbuti, Ricardo Correa. ""Doença do refluxo gastroesofágico: influência da cepa cagA do Helicobacter pylori na resposta terapêutica à inibição da bomba protônica em pacientes com esofagite erosiva leve"." Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/5/5147/tde-02062006-164352/.

Full text
Abstract:
Foram estudados 83 pacientes com esofagite erosiva graus I e II, pela classificação de Savary-Miller modificada, divididos em 3 grupos. Um sem Helicobacter pylori, dois outros com Helicobacter pylori, com e sem o gene cagA. Avaliou-se a participação da bactéria e de seu gene cagA, associados à estudo histopatológico de antro e corpo e à gastrinemia basal, na cicatrização da mucosa do esôfago após tratamento com pantoprazol 40 mg ao dia por 6 semanas. Verificou-se que a presença do Helicobacter pylori, independentemente da presença do gene cagA, facilita a cicatrização esofágica. Indivíduos com
APA, Harvard, Vancouver, ISO, and other styles
9

Rosania, Rosa [Verfasser], Ulrich [Gutachter] Peitz, and Peter [Gutachter] Konturek. "Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel disease : a case-control study / Rosa Rosania ; Gutachter: Ulrich Peitz, Peter Konturek." Magdeburg : Universitätsbibliothek Otto-von-Guericke-Universität, 2020. http://d-nb.info/1219965499/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nordenstedt, Helena. "Gastroesophageal reflux : etiological factors /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-205-7/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pylori therapy"

1

Yoshimasa, Yamamoto, Friedman Herman 1931-, and Hoffman Paul, eds. Helicobacter pylori infection and immunity. Kluwer Academic/Plenum, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

International Symposium on Helicobacter Pylori (2nd 1989 Bad Nauheim, Germany). Helicobacter pylori 1990: Proceedings of the Second International Symposium on Helicobacter Pylori, Bad Nauheim, August 25-26th, 1989. Springer-Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1939-, Menge H., ed. Helicobacter pylori 1991: Proceedings of the Second International Symposium on Helicobacter pylori, Bad Nauheim, August 25-26th, 1989. Springer-Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Murray, Liam. The use of helicobacter pylori eradication therapy in the treatment of duodenal ulceration. R&D Directorate, South and West Regional Health Authority, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Scarpignato, C., and G. Bianchi Porro, eds. Clinical Pharmacology and Therapy of Helicobacter pylori Infection. S. Karger AG, 1999. http://dx.doi.org/10.1159/isbn.978-3-318-00233-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Scarpignato, C., and G. Bianchi Porro, eds. Clinical Pharmacology and Therapy of Helicobacter pylori Infection. S. Karger AG, 2004. http://dx.doi.org/10.1159/isbn.978-3-318-01034-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Menge, H., Guido N. J. Tytgat, Gregor M, Barry J. Marshall, and C. A. M. McNulty. Helicobacter Pylori 1990: Proceedings of the Second International Symposium on Helicobacter Pylori Bad Nauheim, August 25 26th, 1989. Springer, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Scarpignato, C. Clinical Pharmacology and Therapy of Helicobacter Pylori Infection (Progress in Basic and Clinical Pharmacology). S Karger Pub, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

(Editor), C. Scarpignato, and G. Bianchi Porro (Editor), eds. Clinical Pharmacology and Therapy of Helicobacter pylori Infection (Progress in Basic and Clinical Pharmacology, vol 11). S. Karger AG (Switzerland), 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

The great ulcer war: How an axis of an American university research group and a global pharmaceutical company attacked one of the great medical discoveries of the twentieth century. William S. Hughes, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pylori therapy"

1

Yoon, Hyuk. "Concomitant Therapy and Hybrid Therapy." In Helicobacter pylori. Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-287-706-2_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Jung Won. "Concomitant Therapy and Hybrid Therapy." In Helicobacter pylori. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-97-0013-4_47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lee, Ju Yup. "Triple Therapy." In Helicobacter pylori. Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-287-706-2_41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, Ju Yup. "Quadruple Therapy." In Helicobacter pylori. Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-287-706-2_42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yoon, Hyuk. "Sequential Therapy." In Helicobacter pylori. Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-287-706-2_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Ju Yup. "Triple Therapy." In Helicobacter pylori. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-97-0013-4_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lee, Ju Yup. "Quadruple Therapy." In Helicobacter pylori. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-97-0013-4_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lee, Jung Won. "Sequential Therapy." In Helicobacter pylori. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-97-0013-4_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nishizawa, Toshihiro, and Hidekazu Suzuki. "Third-Line Eradication Therapy." In Helicobacter pylori. Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55705-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Molina-Infante, Javier, and David Y. Graham. "Helicobacter pylori Therapy." In Helicobacter pylori Research. Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55936-8_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pylori therapy"

1

Zheng, Chunqian. "Immune Response of Helicobacter pylori and disadvantages of antibiotic therapy." In 2022 International Conference on Social Sciences and Humanities and Arts (SSHA 2022). Atlantis Press, 2022. http://dx.doi.org/10.2991/assehr.k.220401.125.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Harbi, R., S. Mrabet, S. Zaouga, I. Akkari, and E. Ben Jazia. "Efficacy Of Theconcomitant Quadruple Therapy for The Eradication Of Helicobacter Pylori." In ESGE Days 2021. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1724567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ren, Binbin, Haiyan Tan, Binlin Chen, Bin Zheng, Zhangyong Li, and Wei Wang. "Design of pH Measuring in Wireless Therapy Capsule Against Helicobacter Pylori Infections." In 2016 4th International Conference on Machinery, Materials and Computing Technology. Atlantis Press, 2016. http://dx.doi.org/10.2991/icmmct-16.2016.117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Millson, Charles E., Giovanni A. Buonaccorsi, Alexander J. MacRobert, Peter Mlkvy, and Stephen G. Bown. "Fluorescence tissue distribution of methylene blue used for photodynamic therapy of Helicobacter Pylori." In Fifth International Photodynamic Association Biennial Meeting, edited by Denis A. Cortese. SPIE, 1994. http://dx.doi.org/10.1117/12.203417.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Park, E. "Comparison of standard, sequential, and concomitant first line eradication therapy for H. pylori." In 51. Jahrestagung & 29. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH). Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1654628.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sarras, K., E. Ahadzadeh Ghanad, S. Fong, TY Lim, and RP Logan. "PWE-044 A new one week high dose triple therapy for helicobacter pylori infection." In British Society of Gastroenterology, Annual General Meeting, 19–22 June 2017, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2017. http://dx.doi.org/10.1136/gutjnl-2017-314472.289.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"#144 – QUADRUPLE AND DUAL THERAPIES ARE SUPERIOR TO STANDARD CLARITHROMYCIN-BASED TRIPLE THERAPY FOR HELICOBACTER PYLORI FIRST-LINE ERADICATION THERAPY USED IN THE LATIN AMERICAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (Hp-LATAMReg)." In Semana Panamericana de Enfermedades Digestivas. SPED 2023. Editorial Iku Limitada, 2023. http://dx.doi.org/10.46613/congastro2023-144.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Korpela, R., E. Myllyluoma, L. Veijola, et al. "Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomised pilot study." In 13th World Congress of Food Science & Technology. EDP Sciences, 2006. http://dx.doi.org/10.1051/iufost:20060220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Xiaoyong. "IDDF2024-ABS-0102 Efficacy of vonoprazan combined with low-dose amoxicillin dual therapy for helicobacter pylori eradication." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 10 – 11 August 2024. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2024. http://dx.doi.org/10.1136/gutjnl-2024-iddf.256.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Liou, Jyh-Ming, Po-Yueh Chen, Chieh-Chang Chen, et al. "IDDF2019-ABS-0126 Levofloxacin sequential therapy versus bismuth quadruple therapy in the second-line and third-line treatment of helicobacter pylori -a multicenter randomized trial." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.159.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pylori therapy"

1

Cai, Zhaolun. Tailored Therapy for Helicobacter Pylori Eradication: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.3.0166.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yao, Gaoyan, Xiaoyuan Fan, and Dewen Lu. Efficacy and Safety of Probiotic-supplemented Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.7.0051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

DING, YUMING, XIULI ZUO, and YUEYUE LI. Systematic Review and Meta-analysis of 10 and 14 days Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.12.0034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhou, Fang, and Li Xie. The efficacy and safety of Bismuth -containing quadruple therapy with different periods for Helicobacter pylori eradication treatment in China: a systemic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.3.0028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Xi, Xiaomei, and Xingmin Wei. Meta-analysis of the treatment of chronic gastritis infected by Helicobacter pylori by clearing heat and removing dampness combined with quadruple therapy and the mechanism of common drugs. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.2.0007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pylori therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography